Groupe Hospitalier Archet I et II

Nice 6002

0 studies enrolling now · 5 studies all time

What they study most

Advanced Cholangiocarcinoma, FGFR2 Gene Mutation, Melanoma, Metastatic or Unresectable Cutaneous Melanoma, Psoriatic Arthritis

Studies at this site

• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — Stopped early
• Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) — Completed
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma — Completed
• PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis — Completed